Becker U - Search Results

1

Cost-effectiveness of First-line Chronic Lymphocytic Leukemia Treatments When Full-dose Fludarabine Is Unsuitable.

Soini E, Hautala A, Poikonen E, Becker U, Kyttälä M, Martikainen J. Soini E, et al. Among authors: becker u. Clin Ther. 2016 Apr;38(4):889-904.e14. doi: 10.1016/j.clinthera.2016.02.005. Epub 2016 Mar 10. Clin Ther. 2016. PMID: 26970696 Free article.

2

Cost-Effectiveness Model for Chemoimmunotherapy Options in Patients with Previously Untreated Chronic Lymphocytic Leukemia Unsuitable for Full-Dose Fludarabine-Based Therapy.

Becker U, Briggs AH, Moreno SG, Ray JA, Ngo P, Samanta K. Becker U, et al. Value Health. 2016 Jun;19(4):374-82. doi: 10.1016/j.jval.2015.12.018. Epub 2016 Mar 4. Value Health. 2016. PMID: 27325329 Free article.

3

Cost-Effectiveness Analysis of Obinutuzumab for Previously Untreated Chronic Lymphocytic Leukaemia in Portuguese Patients who are Unsuitable for Full-Dose Fludarabine-Based Therapy.

Paquete AT, Miguel LS, Becker U, Pereira C, Pinto CG. Paquete AT, et al. Among authors: becker u. Appl Health Econ Health Policy. 2017 Aug;15(4):501-512. doi: 10.1007/s40258-017-0321-2. Appl Health Econ Health Policy. 2017. PMID: 28342061

4

Cost-effectiveness of casirivimab/imdevimab in patients with COVID-19 in the ambulatory setting.

Jovanoski N, Kuznik A, Becker U, Hussein M, Briggs A. Jovanoski N, et al. Among authors: becker u. J Manag Care Spec Pharm. 2022 May;28(5):555-565. doi: 10.18553/jmcp.2022.21469. Epub 2022 Mar 3. J Manag Care Spec Pharm. 2022. PMID: 35238626

CONCLUSIONS: This economic analysis found that casirivimab/imdevimab is a cost-effective treatment for most ambulatory patients with COVID-19. DISCLOSURES: N. Jovanoski and U. Becker are employees of F Hoffman-La Roche Ltd.; A. Kuznik and M. ...

CONCLUSIONS: This economic analysis found that casirivimab/imdevimab is a cost-effective treatment for most ambulatory patients with COVID-1 …

5

Disappearance of B-Symptoms In Comorbid Patients Receiving First-Line Obinutuzumab (Ga101) -Chlorambucil (G-Clb) Or Rituximab-Chlorambucil (R-Clb) for Chronic Lymphocytic Leukemia (Cll).

Wenk AS, Becker U, Klawitter S, Wiesner C, Bernhardt A. Wenk AS, et al. Among authors: becker u. Value Health. 2014 Nov;17(7):A522. doi: 10.1016/j.jval.2014.08.1636. Epub 2014 Oct 26. Value Health. 2014. PMID: 27201638 Free article. No abstract available.

6

Health state utilities for chronic lymphocytic leukemia: importance of prolonging progression-free survival.

Kosmas CE, Shingler SL, Samanta K, Wiesner C, Moss PA, Becker U, Lloyd AJ. Kosmas CE, et al. Among authors: becker u. Leuk Lymphoma. 2015 May;56(5):1320-6. doi: 10.3109/10428194.2014.961012. Epub 2015 Jan 14. Leuk Lymphoma. 2015. PMID: 25213185

7

Quantifying the relationship between disability progression and quality of life in patients treated for NMOSD: Insights from the SAkura studies.

Levy M, Haycox AR, Becker U, Costantino C, Damonte E, Klingelschmitt G, von Büdingen HC, Wallenstein G, Maio DD, Szczechowski L. Levy M, et al. Among authors: becker u. Mult Scler Relat Disord. 2022 Jan;57:103332. doi: 10.1016/j.msard.2021.103332. Epub 2021 Oct 15. Mult Scler Relat Disord. 2022. PMID: 35158426 Free article. Clinical Trial.

8

Severity of COVID-19 and adverse long-term outcomes: a retrospective cohort study based on a US electronic health record database.

Jovanoski N, Chen X, Becker U, Zalocusky K, Chawla D, Tsai L, Borm M, Neighbors M, Yau V. Jovanoski N, et al. Among authors: becker u. BMJ Open. 2021 Dec 10;11(12):e056284. doi: 10.1136/bmjopen-2021-056284. BMJ Open. 2021. PMID: 34893488 Free PMC article.

9

Dynamic impact force and association with structural damage to the knee joint: an ex-vivo study.

Brill R, Wohlgemuth WA, Hempfling H, Bohndorf K, Becker U, Welsch U, Kamp A, Roemer FW. Brill R, et al. Among authors: becker u. Ann Anat. 2014 Dec;196(6):456-63. doi: 10.1016/j.aanat.2014.07.007. Epub 2014 Aug 14. Ann Anat. 2014. PMID: 25175150

10

Code generation in ORCA: progress, efficiency and tight integration.

Lechner MH, Papadopoulos A, Sivalingam K, Auer AA, Koslowski A, Becker U, Wennmohs F, Neese F. Lechner MH, et al. Among authors: becker u. Phys Chem Chem Phys. 2024 May 20. doi: 10.1039/d4cp00444b. Online ahead of print. Phys Chem Chem Phys. 2024. PMID: 38767596

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

404 results

Search Page